Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 266

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

Open access
Mitjà, Oriol, Corbacho-Monné, Marc, Ubals, Maria, Alemany, Andrea, Suñer, Clara, Tebé, Cristian, Tobias, Aurelio, Peñafiel, Judith, Ballana, Ester, Pérez, Carla A., Admella, Pol, Riera-Martí, Núria, Laporte, Pep, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ara, Jordi, Argimon, Josep M., Cuatrecasas, Gabriel, Cañadas, Paz, Elizalde-Torrent, Aleix, Fabregat, Robert, Farré, Magí, Forcada, Anna, Flores-Mateo, Gemma, López, Cristina, Muntada, Esteve, Nadal, Núria, Narejos, Silvia, Nieto, Aroa, Prat, Nuria, Puig, Jordi, Quiñones, Carles, Ramírez-Viaplana, Ferran, Reyes-Urueña, Juliana, Riveira-Muñoz, Eva, Ruiz, Lidia, Sanz, Sergi, Sentís, Alexis, Sierra, Alba, Velasco, César, Vivanco-Hidalgo, Rosa M., Zamora, Juani, Casabona, Jordi, Vall-Mayans, Martí, González-Beiras, Camila, Clotet, Bonaventura·2021·New England Journal of Medicine

Abstract

BACKGROUND: Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking. METHODS: We conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. We randomly assigned clusters of contacts to the hydroxychloroquine group (which received the drug at a dose of 800 mg once, followed by 400 mg daily for 6 days) or to the usual-care group (which received no specific therapy). The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, defined by symptoms compatible with Covid-19 or a positive PCR test regardless of symptoms. Adverse events were assessed for up to 28 days. RESULTS: The analysis included 2314 healthy contacts of 672 index case patients with Covid-19 who were identified between March 17 and April 28, 2020. A total of 1116 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care. Results were similar in the hydroxychloroquine and usual-care groups with respect to the incidence of PCR-confirmed, symptomatic Covid-19 (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]). In addition, hydroxychloroquine was not associated with a lower incidence of SARS-CoV-2 transmission than usual care (18.7% and 17.8%, respectively). The incidence of adverse events was higher in the hydroxychloroquine group than in the usual-care group (56.1% vs. 5.9%), but no treatment-related serious adverse events were reported. CONCLUSIONS: Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient. (Funded by the crowdfunding campaign YoMeCorono and others; BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2021801

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 266

Metadata

Authors
Mitjà, O., Corbacho-Monné, M., Ubals, M., Alemany, A., Suñer, C., Tebé, C., Tobias, A., Peñafiel, J., Ballana, E., Pérez, C. A., Admella, P., Riera-Martí, N., Laporte, P., Mitjà, J., Clua, M., Bertran, L., Sarquella, M., Gavilán, S., Ara, J., Argimon, J. M., Cuatrecasas, G., Cañadas, P., Elizalde-Torrent, A., Fabregat, R., Farré, M., Forcada, A., Flores-Mateo, G., López, C., Muntada, E., Nadal, N., Narejos, S., Nieto, A., Prat, N., Puig, J., Quiñones, C., Ramírez-Viaplana, F., Reyes-Urueña, J., Riveira-Muñoz, E., Ruiz, L., Sanz, S., Sentís, A., Sierra, A., Velasco, C., Vivanco-Hidalgo, R. M., Zamora, J., Casabona, J., Vall-Mayans, M., González-Beiras, C., & Clotet, B.
Venue
New England Journal of Medicine
Published
2021-02-04
Volume
384
Issue
5
Pages
417-427
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3109912694
Cited by
266
References
24
FWCI
7.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. https://app.cochat.ai/papers/10.1056/nejmoa2021801
The paper
Mitjà, O., Corbacho-Monné, M., Ubals, M., Alemany, A., Suñer, C., Tebé, C., Tobias, A., Peñafiel, J., Ballana, E., Pérez, C. A., Admella, P., Riera-Martí, N., Laporte, P., Mitjà, J., Clua, M., Bertran, L., Sarquella, M., Gavilán, S., Ara, J., . . . Clotet, B. (2021). A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2021801

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.